S. Rossomanno

Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients.

G. Franceschini, E. Favari, M. Adorni, 2013, Journal of clinical lipidology.

First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors

M. Hidalgo, T. Nayak, K. Stubenrauch, 2017, Clinical Cancer Research.

Co-deposition of salmeterol and fluticasone propionate by a combination inhaler.

Brandon Whitcher, Alison Moore, Henry Chrystyn, 2006, International journal of pharmaceutics.

Xanthophylls, Phytosterols and Pre-β1-HDL are Differentially Affected by Fenofibrate and Niacin HDL-Raising in a Cross-Over Study

H. Gylling, D. Kallend, B. Asztalos, 2013, Lipids.

Vanucizumab mode of action: Serial biomarkers in plasma, tumor, and skin-wound-healing biopsies

M. Hidalgo, M. Martínez-García, K. Lechner, 2020, Translational oncology.

The McCAVE Trial: Vanucizumab plus mFOLFOX‐6 Versus Bevacizumab plus mFOLFOX‐6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)

H. Hurwitz, J. Bendell, K. Lechner, 2019, The oncologist.

Predictors of placebo response in three large clinical trials of the V1a receptor antagonist balovaptan in autism spectrum disorder

Russell H. Tobe, J. Veenstra-VanderWeele, Yajing Zhu, 2023, Neuropsychopharmacology.

Final results of the McCAVE trial: A double-blind, randomized phase 2 study of vanucizumab (VAN) plus FOLFOX vs. bevacizumab (BEV) plus FOLFOX in patients (pts) with previously untreated metastatic colorectal carcinoma (mCRC).

Cristina Santos, H. Hurwitz, J. Bendell, 2017 .